Helsinn Healthcare
Helsinn Healthcare, a Swiss-based pharmaceutical company, has established itself as a leader in the oncology and supportive care sectors since its founding in 1977. Headquartered in Lugano, Switzerland, Helsinn operates globally, with significant presence in Europe, North America, and Asia. The company is renowned for its innovative approach to developing high-quality products that enhance the quality of life for cancer patients, including its flagship anti-emetic treatments. With a strong commitment to research and development, Helsinn has achieved notable milestones, including strategic partnerships and a robust pipeline of therapies. Its dedication to patient-centric solutions and a focus on unmet medical needs have positioned Helsinn as a trusted name in the healthcare industry, recognised for its contributions to cancer care and supportive therapies.
DitchCarbon Score
How does Helsinn Healthcare's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Helsinn Healthcare's score of 19 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Helsinn Healthcare's reported carbon emissions
In 2023, Helsinn Healthcare reported total carbon emissions of approximately 6,200,000 kg CO2e, comprising 2,245,000 kg CO2e from Scope 1, 45,000 kg CO2e from Scope 2, and 4,739,000 kg CO2e from Scope 3 emissions. This reflects a significant reliance on upstream activities, particularly in purchased goods and services, which accounted for about 1,793,300 kg CO2e. Over the years, Helsinn has demonstrated a commitment to reducing its carbon footprint. For instance, in 2022, the company recorded total emissions of about 6,000,000 kg CO2e, indicating a slight increase in 2023. However, from 2015 to 2023, there have been fluctuations in emissions, with notable reductions in Scope 1 emissions from 2,899,000 kg CO2e in 2015 to 2,245,000 kg CO2e in 2023. Despite these figures, Helsinn Healthcare has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to focus on understanding and managing its emissions across all scopes, particularly in light of the increasing importance of sustainability in the healthcare sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2012 | 2013 | 2014 | 2015 | 2016 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 2,955,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | - | 0,000,000 | 0,000,000 | 000,000 | 000,000 | 00,000 |
| Scope 3 | - | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Helsinn Healthcare is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
